Increased local procoagulant action: a mechanism contributing to the favorable hemostatic effect of recombinant FVIIa in PLT disorders.

This paper reports the procoagulant effect of rFVIIa in experimental thrombocytopenia, and in thromboasthenic platelets due to natural or experimentally induced glycoprotein deficiency. It shows that rFVIIa improved fibrin deposition, thrombin generation and platelet interaction at sites of vascular damage. These observations may explain the hemostatic effects of rFVIIa in controlling hemorrhage in patients with […]

The interaction between platelets and factor VII/VIIa.

This is a clearly written article detailing the mechanism of action of rFVIIa and its interaction with tissue factor and platelets leading to its hemostatic effect in hemophilia patients with inhibitors and those with platelet disorders. – Maadh Aldouri

Treatment of bleeding in severe necrotizing pancreatitis with recombinant factor Vlla.

This is a letter to the editor describing a 50 yr old woman who presented with pancreatitis but subsequently required laparatomy for pancreatectomy, splenectomy and subtotal gastrectomy. There was profuse bleeding which required massive transfusion support. Bleeding eventually dramatically responded to doses of rFVIIa at 120 μg/kg. – Maadh Aldouri

Treatment of critical bleeding in the future intensive care unit. [Editorial]

Uncontrolled bleeding remains a major problem in intensive care and emergency medicine which still requires effective and innovative treatment options. This editorial highlights that there is growing evidence on the efficacy of rFVIIa (Novoseven) in controlling such bleeding, and that clinical trials in different patient populations are required to assess its efficacy and safety. – […]

Ongoing NovoSeven((R)) trials.

This paper reviews the current trials for the extended use of rFVIIa outside hemophilia patients with inhibitors. These areas include thrombocytopenia, liver disease, trauma, intracerebral hemorrhage, surgery, and anticoagulation. – M. Aldouri

NovoSeven: mode of action and use in acquired haemophilia.

This is a very good review on the use and mechanism of action of rFVIIa in acquired hemophilia. It reviews the physiological coagulation pathway and the central role of factor VII and tissue factor, and the changes which occur in hemophiliac patients. It also reviews the pathogenesis of acquired hemophilia and the results of using […]

Haemorrhagic complications of thrombocytopenia and oral anticoagulation: is there a role for recombinant activated factor VII?

This paper reviews the existing evidence supporting the efficacy and safety of rFVIIa in treating bleeding manifestations in patients with thrombocytopenia or those with excessive anticoagulation with warfarin. Currently this is in the form of case report or small series which showed efficacy of rFVIIa in reducing bleeding, shortening of bleeding time or reduction of […]